此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项有助于管理和治疗克罗恩病的 CDPATH™ 研究 (COMPASS-CD)

2026年10月5日 更新者:Takeda

一项评估克罗恩病风险预测工具 CDPATH™ 在现实世界中的使用的第 4 阶段研究

CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their Crohn's disease. The number of visits will be decided by the study clinic according to their standard practice.

研究概览

地位

完全的

条件

详细说明

The tool being tested in this study is called CDPATH™. CDPATH™ is being used to provide a graphical representation of an individual participant's risk of developing a CD-related complication within three years, leveraging known participant risk factors based on clinical, serologic and genetic variables to help people categorize risk who have CD. This study will gather data on the use of the tool in real-world settings to inform practical use of CDPATH™.

The study will enroll approximately 200 patients. Participants and health care providers (HCPs) will be surveyed to understand their satisfaction with the CDPATH™ process and with their treatment choice.

This multi-center trial will be conducted in the United States. The overall time to participate in this study is 36 months. Participants will make multiple visits to the HCP's clinic, and data will be collected approximately every six months up to 3 years, based on the timing of routine follow-up appointments for assessment.

研究类型

介入性

注册 (实际的)

241

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Arizona
      • Phoenix、Arizona、美国、85032
        • Arizona Arthritis & Rheumatology Research, PLLC
    • California
      • Loma Linda、California、美国、92357
        • VA Loma Linda Healthcare System
      • Murrieta、California、美国、92563
        • United Medical Doctors
      • Newport Beach、California、美国、92663
        • University of Southern California Medical Center
      • Orange、California、美国、92868
        • University of California at Irvine Medical Center
      • Orange、California、美国、92868
        • Clinnova Research Solutions
    • Colorado
      • Aurora、Colorado、美国、80014
        • Kaiser Permanate of Colorado
    • Connecticut
      • Hamden、Connecticut、美国、06518
        • Medical Research Center of Connecticut, LLC
    • Florida
      • Clearwater、Florida、美国、33762
        • West Central Gastroenterology d/b/a Gastro Florida
      • Pensacola、Florida、美国、32503
        • Gastroenterology Associates of Pensacola, PA
    • Idaho
      • Idaho Falls、Idaho、美国、83404
        • Grand Teton Research Group, PLL
    • Illinois
      • Arlington Heights、Illinois、美国、60005
        • GI Alliance
      • Gurnee、Illinois、美国、60031
        • GI Alliance
      • Northbrook、Illinois、美国、60062
        • Comprehensive Gastrointestinal Health
      • Rockford、Illinois、美国、61107
        • Rockford Gastroenterology Associates, Ltd.
    • Indiana
      • Indianapolis、Indiana、美国、46202
        • Indiana University
    • Iowa
      • Clive、Iowa、美国、50325
        • Iowa Digestive Disease Center
      • Iowa City、Iowa、美国、52242-1009
        • University of Iowa Hospitals & Clinics
    • Kansas
      • Kansas City、Kansas、美国、66160
        • University of Kansas Medical Center Research Institute, Inc.
    • Louisiana
      • Baton Rouge、Louisiana、美国、70809
        • GI Alliance - Baton Rouge
      • Shreveport、Louisiana、美国、71105
        • Louisiana Research Center, LLC
    • Maryland
      • Columbia、Maryland、美国、21045
        • Gastro Center of Maryland
    • Massachusetts
      • Burlington、Massachusetts、美国、01805
        • Lahey Clinic Inc. - PARENT ACCOUNT
      • Worcester、Massachusetts、美国、01655
        • UMASS Memorial Medical Center
    • New Mexico
      • Albuquerque、New Mexico、美国、87131-0001
        • University of New Mexico
    • New York
      • New York、New York、美国、10075-1850
        • Lenox Hill Hospital
    • Ohio
      • Beavercreek、Ohio、美国、45431
        • Clinical Inquest Center Ltd
      • Dayton、Ohio、美国、45415
        • Dayton Gastroenterology, Inc
    • Oregon
      • Portland、Oregon、美国、97220-9442
        • The Oregon Clinic, P.C.
    • Pennsylvania
      • Camp Hill、Pennsylvania、美国、17011
        • Susquehanna Research Group, LLC
      • Pittsburgh、Pennsylvania、美国、15213
        • University of Pittsburgh Medical Center Health System
      • Pittsburgh、Pennsylvania、美国、15212
        • Allegheny Center for Digestive Health
      • Uniontown、Pennsylvania、美国、15401
        • Frontier Clinical Research, LLC
    • South Carolina
      • Summerville、South Carolina、美国、29486
        • Palmetto Primary Care Physician Division of Gastroenterology
    • South Dakota
      • Rapid City、South Dakota、美国、57701
        • Rapid City Medical Center, LLC
    • Tennessee
      • Nashville、Tennessee、美国、37204
        • Vanderbilt University Medical Center
    • Texas
      • Austin、Texas、美国、78712
        • The University of Texas at Austin
      • Houston、Texas、美国、77030
        • Baylor College of Medicine
      • Southlake、Texas、美国、76092
        • GI Alliance - Southlake
    • Utah
      • Ogden、Utah、美国、84403
        • Care Access Research Berkley
      • Salt Lake City、Utah、美国、84132
        • University of Utah
    • Virginia
      • Fairfax、Virginia、美国、22031
        • GCGA Physicians LLC
      • Lynchburg、Virginia、美国、24502
        • Gastroenterology Associates
    • Washington
      • Bellevue、Washington、美国、98405
        • GI Alliance

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Has an initial diagnosis of CD established within five years prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report (if available).
  2. Has agreed to use the CDPATH™ tool.
  3. Has reliable access to the internet and is willing to answer electronic patient-reported outcomes (ePROs) throughout the study.

Exclusion Criteria:

  1. Has had known complications from CD including but not limited to: bowel stricture, CD-related intra-abdominal abscess, internal penetrating disease (known fistula other than perianal fistula), non-perianal surgery, bowel resection, or stricturoplasty. A perianal fistula or abscess without other signs of penetrating disease is allowed.
  2. Has had any non-CD-related abdominal surgery.
  3. Has received investigational biologic or nonbiologic agents for the treatment of CD in an investigational protocol. Approved biologic or nonbiologic agents for CD are allowed.
  4. Has previously used CDPATH™ or PROSPECT results to assess CD risk for complications.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:诊断
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:CDPATH™

Participants with CD will be using CDPATH™ tool. Clinical data will be collected via an ongoing registry. Participants and health care provider (HCP)-reported outcomes data will be collected periodically once every 6 months for up to 36 months via electronic surveys. Two baseline blood samples will be collected at screening for CDPATH™ analysis. 1 additional sample will be collected for future potential biomarker analysis.

Crohn's disease risk prediction tool.

其他名称:
  • 前景

Three blood samples will be drawn.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of Participants in Real-world Practice in Each Risk Category at Baseline Based on the CDPATH™ Tool Results
大体时间:Baseline (Day 1)

The risk profile of an individual participant with CD is the output of the CDPATH™ tool. Categories for CD includes low, medium, high risk of developing a CD complication within 3 years.

Baseline (Day 1)

次要结果测量

结果测量
措施说明
大体时间
Percentage of Participants with Specific Treatment Path and Choice Based on CDPATH™ Tool, Stratified According to Risk Category
大体时间:Up to 36 months

Treatment path (i.e., sequence over time) and choice, by low, medium and high risk, will be chosen to characterize treatment path and choice based on risk stratification.

Up to 36 months
Change From Baseline in Decisional Conflict Scale (DCS) Score
大体时间:Baseline, then every 6 months up to 36 months

DCS is a validated electronic patient-reported outcome (ePRO) collected via electronically administered patient surveys. It measures personal perceptions of the following responses: uncertainty in choosing options, modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in decision making, and effective decision making such as feeling the choice is informed, values-based, likely to be implemented and expressing satisfaction with the choice. DCS involves answering 11 questions of PRO, of which 10 questions can be answered as yes (score = 0) or unsure (score = 2) or no (score =4). The total score will range from 0 to 40. Higher score indicates higher decisional conflict.

Baseline, then every 6 months up to 36 months
Change From Baseline in Work Productivity and Activity Impairment Questionnaire - CD Version (WPAI-CD) Score
大体时间:Baseline, then every 6 months up to 36 months

WPAI-CD is a validated ePRO collected via electronically administered patient surveys. It consists of six questions that evaluate 4 domain scores: absenteeism (i.e., work time missed), presenteeism (i.e., reduced work productivity), overall work impairment, and activity impairment. Scores are expressed as a percentage of impairment, where higher scores indicate greater impairment and reduced productivity. The total score ranges from 0 (no impairment) to 100% (total loss of work productivity).

Baseline, then every 6 months up to 36 months
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Scale Score
大体时间:Baseline, then every 6 months up to 36 months

PROMIS Global Health scale is a validated ePRO collected via electronically administered patient surveys. It is a 10-item PRO measuring the overall evaluation of one's physical and mental health. The total score ranges from 0 to 100. The final score will be represented by the T-score metric, in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. A higher PROMIS T-score represents more of the concept being measured (higher Global Health score indicate better health).

Baseline, then every 6 months up to 36 months
Patient-Reported Satisfaction and Experience Score with the CDPATH™ Tool
大体时间:Up to 36 months

Participant's satisfaction and experience with the CDPATH™ tool will be assessed based on 15 questions. Negative responses/lower score to/in these questions indicates less satisfaction whereas positive responses/higher score indicates satisfaction with the tool.

Up to 36 months
Number of Participants with Clinical Outcomes
大体时间:Up to 36 months

Participants with clinical outcomes describing the disease burden based on treatment path and controlling for risk strata will be reported.

Up to 36 months
Percentage of Participants with Healthcare Resource Utilization
大体时间:Up to 36 months

Healthcare resource includes healthcare provider (HCP) visits/referrals, visit to emergency room, hospitalizations, surgery, new CD-related complications, and diagnostic evaluations (e.g., imaging, colonoscopy, etc.).

Up to 36 months
Change from First Assessment in Health Care Provider (HCP)-reported Assessment of the Feasibility and Usability of the CDPATH™ Tool
大体时间:First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)

HCP-reported CDPATH™ satisfaction data will be collected directly from HCPs via electronically administered HCP surveys and entered into the eCRF. HCPs will be queried regarding their satisfaction and experience with the general process, the ease of incorporating the tool in their everyday practice, and the impact of the tool on their treatment recommendations and participant communications. For the 6 questions, HCP will rate on 1-5 scale where, 1=strongly disagree and 5=strongly agree. For remaining 4 questions, written feedback from HCP will be consider. Overall positive responses will indicate higher feasibility and usability.

First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:Study Director、Takeda

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年6月25日

初级完成 (实际的)

2026年8月27日

研究完成 (实际的)

2026年8月27日

研究注册日期

首次提交

2021年3月19日

首先提交符合 QC 标准的

2021年3月19日

首次发布 (实际的)

2021年3月22日

研究记录更新

最后更新发布 (实际的)

2026年10月8日

上次提交的符合 QC 标准的更新

2026年10月5日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

IPD 共享访问标准

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅